IL-6 to the res­cue? Sanofi, Re­gen­eron bar­rel ahead in­to an­oth­er piv­otal ef­fort test­ing Kevzara for Covid-19

Sanofi and Re­gen­eron have hus­tled up a sec­ond piv­otal tri­al for their IL-6 drug Kevzara as a po­ten­tial ther­a­py for se­vere cas­es of Covid-19. The part­ners swift­ly as­sem­bled a study draw­ing pa­tients from Italy, Spain, Ger­many, France, Cana­da and Rus­sia, plan­ning to sign up 300 pa­tients in a Phase II to test a low and high dose of Kevzara against place­bo, set­ting the stage for the Phase III fol­lowup.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER